Larvol Delta - Caliways-CBL514-Combination-Therapy-Cleared-by-US-FDA-for-Phase-2-Trial-Pivotal-Phase-3-Trial-SUPREME01-Initiates-Enrollment--

CBL-514 - Caliway Biopharmaceuticals

https://www.prnewswire.com/news-releases/caliways-cbl-514-combination-therapy-cleared-by-us-fda-for-phase-2-trial-pivotal-phase-3-trial-supreme-01-initiates-enrollment-302859956.html

Aug 25, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next